180 related articles for article (PubMed ID: 37952690)
1. CCDC92 deficiency ameliorates podocyte lipotoxicity in diabetic kidney disease.
Zuo F; Wang Y; Xu X; Ding R; Tang W; Sun Y; Wang X; Zhang Y; Wu J; Xie Y; Liu M; Wang Z; Yi F
Metabolism; 2024 Jan; 150():155724. PubMed ID: 37952690
[TBL] [Abstract][Full Text] [Related]
2. CCDC92 promotes podocyte injury by regulating PA28α/ABCA1/cholesterol efflux axis in type 2 diabetic mice.
Zuo FW; Liu ZY; Wang MW; Du JY; Ding PZ; Zhang HR; Tang W; Sun Y; Wang XJ; Zhang Y; Xie YS; Wu JC; Liu M; Wang ZY; Yi F
Acta Pharmacol Sin; 2024 May; 45(5):1019-1031. PubMed ID: 38228909
[TBL] [Abstract][Full Text] [Related]
3. MYDGF attenuates podocyte injury and proteinuria by activating Akt/BAD signal pathway in mice with diabetic kidney disease.
He M; Li Y; Wang L; Guo B; Mei W; Zhu B; Zhang J; Ding Y; Meng B; Zhang L; Xiang L; Dong J; Liu M; Xiang L; Xiang G
Diabetologia; 2020 Sep; 63(9):1916-1931. PubMed ID: 32588068
[TBL] [Abstract][Full Text] [Related]
4. PFKP Activation Ameliorates Foot Process Fusion in Podocytes in Diabetic Kidney Disease.
Zhang Z; Liang W; Luo Q; Hu H; Yang K; Hu J; Chen Z; Zhu J; Feng J; Zhu Z; Chi Q; Ding G
Front Endocrinol (Lausanne); 2021; 12():797025. PubMed ID: 35095764
[TBL] [Abstract][Full Text] [Related]
5. Elevation of JAML Promotes Diabetic Kidney Disease by Modulating Podocyte Lipid Metabolism.
Fu Y; Sun Y; Wang M; Hou Y; Huang W; Zhou D; Wang Z; Yang S; Tang W; Zhen J; Li Y; Wang X; Liu M; Zhang Y; Wang B; Liu G; Yu X; Sun J; Zhang C; Yi F
Cell Metab; 2020 Dec; 32(6):1052-1062.e8. PubMed ID: 33186558
[TBL] [Abstract][Full Text] [Related]
6. miR-4645-3p attenuates podocyte injury and mitochondrial dysfunction in diabetic kidney disease by targeting Cdk5.
Zhang Y; Xia S; Tian X; Yuan L; Gao Y; Liu D; Qi H; Wang S; Liu Z; Li Y; Zhao Z; Liu W
FASEB J; 2024 May; 38(10):e23668. PubMed ID: 38742811
[TBL] [Abstract][Full Text] [Related]
7. Reducing VEGF-B Signaling Ameliorates Renal Lipotoxicity and Protects against Diabetic Kidney Disease.
Falkevall A; Mehlem A; Palombo I; Heller Sahlgren B; Ebarasi L; He L; Ytterberg AJ; Olauson H; Axelsson J; Sundelin B; Patrakka J; Scotney P; Nash A; Eriksson U
Cell Metab; 2017 Mar; 25(3):713-726. PubMed ID: 28190774
[TBL] [Abstract][Full Text] [Related]
8. STING deletion alleviates podocyte injury through suppressing inflammation by targeting NLRP3 in diabetic kidney disease.
Yang X; Chen Z; Luo Z; Yang D; Hao Y; Hu J; Feng J; Zhu Z; Luo Q; Zhang Z; Liang W; Ding G
Cell Signal; 2023 Sep; 109():110777. PubMed ID: 37329999
[TBL] [Abstract][Full Text] [Related]
9. Podocyte Injury in Diabetic Kidney Disease in Mouse Models Involves TRPC6-mediated Calpain Activation Impairing Autophagy.
Salemkour Y; Yildiz D; Dionet L; 't Hart DC; Verheijden KAT; Saito R; Mahtal N; Delbet JD; Letavernier E; Rabant M; Karras A; van der Vlag J; Nijenhuis T; Tharaux PL; Lenoir O
J Am Soc Nephrol; 2023 Nov; 34(11):1823-1842. PubMed ID: 37678257
[TBL] [Abstract][Full Text] [Related]
10. GPR43 activation-mediated lipotoxicity contributes to podocyte injury in diabetic nephropathy by modulating the ERK/EGR1 pathway.
Lu J; Chen PP; Zhang JX; Li XQ; Wang GH; Yuan BY; Huang SJ; Liu XQ; Jiang TT; Wang MY; Liu WT; Ruan XZ; Liu BC; Ma KL
Int J Biol Sci; 2022; 18(1):96-111. PubMed ID: 34975320
[No Abstract] [Full Text] [Related]
11. PTPN14 deficiency alleviates podocyte injury through suppressing inflammation and fibrosis by targeting TRIP6 in diabetic nephropathy.
Lin Y; Shao Z; Zhao M; Li J; Xu X
Biochem Biophys Res Commun; 2021 Apr; 550():62-69. PubMed ID: 33684622
[TBL] [Abstract][Full Text] [Related]
12. RNA-binding proteins tristetraprolin and human antigen R are novel modulators of podocyte injury in diabetic kidney disease.
Guo J; Lei M; Cheng F; Liu Y; Zhou M; Zheng W; Zhou Y; Gong R; Liu Z
Cell Death Dis; 2020 Jun; 11(6):413. PubMed ID: 32487989
[TBL] [Abstract][Full Text] [Related]
13. p66Shc regulates podocyte autophagy in high glucose environment through the Notch-PTEN-PI3K/Akt/mTOR pathway.
Zheng D; Tao M; Liang X; Li Y; Jin J; He Q
Histol Histopathol; 2020 Apr; 35(4):405-415. PubMed ID: 31650524
[TBL] [Abstract][Full Text] [Related]
14. Klotho inhibits renal ox-LDL deposition via IGF-1R/RAC1/OLR1 signaling to ameliorate podocyte injury in diabetic kidney disease.
Jiang W; Gan C; Zhou X; Yang Q; Chen D; Xiao H; Dai L; Chen Y; Wang M; Yang H; Li Q
Cardiovasc Diabetol; 2023 Oct; 22(1):293. PubMed ID: 37891556
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy.
Wu M; Yang Z; Zhang C; Shi Y; Han W; Song S; Mu L; Du C; Shi Y
Metabolism; 2021 May; 118():154748. PubMed ID: 33675822
[TBL] [Abstract][Full Text] [Related]
16. JAK/STAT pathway promotes the progression of diabetic kidney disease via autophagy in podocytes.
Chen D; Liu Y; Chen J; Lin H; Guo H; Wu Y; Xu Y; Zhou Y; Zhou W; Lu R; Zhou J; Wu J
Eur J Pharmacol; 2021 Jul; 902():174121. PubMed ID: 33901462
[TBL] [Abstract][Full Text] [Related]
17. Placental Mesenchymal Stem Cells Alleviate Podocyte Injury in Diabetic Kidney Disease by Modulating Mitophagy via the SIRT1-PGC-1alpha-TFAM Pathway.
Han X; Wang J; Li R; Huang M; Yue G; Guan L; Deng Y; Cai W; Xu J
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902127
[TBL] [Abstract][Full Text] [Related]
18. CPT1A Protects Podocytes From Lipotoxicity and Apoptosis In Vitro and Alleviates Diabetic Nephropathy In Vivo.
Xie Y; Yuan Q; Tang B; Xie Y; Cao Y; Qiu Y; Zeng J; Wang Z; Su H; Zhang C
Diabetes; 2024 Jun; 73(6):879-895. PubMed ID: 38506804
[TBL] [Abstract][Full Text] [Related]
19. A NOX4/TRPC6 Pathway in Podocyte Calcium Regulation and Renal Damage in Diabetic Kidney Disease.
Ilatovskaya DV; Blass G; Palygin O; Levchenko V; Pavlov TS; Grzybowski MN; Winsor K; Shuyskiy LS; Geurts AM; Cowley AW; Birnbaumer L; Staruschenko A
J Am Soc Nephrol; 2018 Jul; 29(7):1917-1927. PubMed ID: 29793963
[No Abstract] [Full Text] [Related]
20. IGFBP-1 expression is reduced in human type 2 diabetic glomeruli and modulates β1-integrin/FAK signalling in human podocytes.
Lay AC; Hale LJ; Stowell-Connolly H; Pope RJP; Nair V; Ju W; Marquez E; Rollason R; Hurcombe JA; Hayes B; Roberts T; Gillam L; Allington J; Nelson RG; Kretzler M; Holly JMP; Perks CM; McArdle CA; Welsh GI; Coward RJM
Diabetologia; 2021 Jul; 64(7):1690-1702. PubMed ID: 33758952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
